Landscape review of global real-world data sources for studying medication use in pregnancy and lactation that support regulatory decision making

被引:2
作者
Davis, Kourtney [1 ]
Yost, Emily [1 ,6 ]
Brauneis, Jacquelyne [2 ]
Krumme, Alexis [1 ]
Geldhof, Anja [3 ]
Tuck, Astrud [4 ]
Sylvester, Shirley [5 ]
Ephross, Sara [2 ]
机构
[1] Janssen Res & Dev LLC, Global Epidemiol, Raritan, NJ USA
[2] Syneos Hlth, Real World & Late Phase, Morrisville, NC USA
[3] Janssen Bol BV, Med Affairs, Leiden, Netherlands
[4] Janssen Res & Dev LLC, Data Sci, New Brunswick, NJ USA
[5] Johnson & Johnson, Global Publ Hlth, Zug, Switzerland
[6] Janssen Res & Dev LLC, Dept Epidemiol, 1125 Trenton Harbourton Rd, Titusville, NJ 08560 USA
关键词
breastfeeding; mother-infant; pharmacoepidemiology; pregnancy; real-world data;
D O I
10.1002/pds.5711
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose: Most pregnant people take at least one medication during gestation or while breastfeeding, however data are lacking on the safety of medication use in these populations. We conducted a landscape review of real-world data sources specific to medication use in pregnancy and breastfeeding populations that have met, or have potential to meet, health authorities' requirements for post-authorization safety studies.Methods: A 2-phase approach identified data sources from literature, publicly available registers of non-interventional post-authorization studies of pregnant women, existing database inventories, and emerging data sources known to the authors.Results: Required key attributes were assessed according to current regulatory guidance, resulting in selection of 49 suitable data sources. All global regions were represented, with North America (37%) and Europe (33%) most common; 12% of the data sources included pregnancy information from low-to middle-income countries. Administrative healthcare claims (25%) and electronic healthcare records (21%) comprised the largest types of data sources. Across data sources, 53% were managed by national or regional governments, 27% by industry, and 20% by academic institutions. Maternal age, diagnoses, prenatal care, and reproductive history were available in most, whereas fewer included demographic data (e.g., race/ethnicity). Breastfeeding data were collected in 37% of the final data sources.Conclusion: We conducted a systematic approach to data source evaluation of pregnancy and breastfeeding to be used as a resource for investigators to consider when designing pregnancy-related research studies to satisfy regulatory requirements.
引用
收藏
页数:22
相关论文
共 50 条
  • [41] Contemporary use of real-world data for clinical trial conduct in the United States: a scoping review
    Rogers, James R.
    Lee, Junghwan
    Zhou, Ziheng
    Cheung, Ying Kuen
    Hripcsak, George
    Weng, Chunhua
    JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2021, 28 (01) : 144 - 154
  • [42] Big Data and Real-World Data Based Cost-Effectiveness Studies and Decision-Making Models: A Systematic Review and Analysis (vol 12, 700012, 2021)
    Lu, Z. Kevin
    Xiong, Xiaomo
    Lee, Taiying
    Wu, Jun
    Yuan, Jing
    Jiang, Bin
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [43] Quality Criteria for Real-world Data in Pharmaceutical Research and Health Care Decision-making: Austrian Expert Consensus
    Klimek, Peter
    Baltic, Dejan
    Brunner, Martin
    Degelsegger-Marquez, Alexander
    Garhoefer, Gerhard
    Gouya-Lechner, Ghazaleh
    Herzog, Arnold
    Jilma, Bernd
    Kaehler, Stefan
    Mikl, Veronika
    Mraz, Bernhard
    Ostermann, Herwig
    Roehl, Claas
    Scharinger, Robert
    Stamm, Tanja
    Strassnig, Michael
    Wirthumer-Hoche, Christa
    Pleiner-Duxneuner, Johannes
    JMIR MEDICAL INFORMATICS, 2022, 10 (06)
  • [44] Mining real-world high dimensional structured data in medicine and its use in decision support. Some different perspectives on unknowns, interdependency, and distinguishability
    Robson, Barry
    Boray, S.
    Weisman, J.
    COMPUTERS IN BIOLOGY AND MEDICINE, 2022, 141
  • [45] Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers
    Murphy, Linda A.
    Akehurst, Ron
    Sola-Morales, Oriol
    Cunningham, David
    Mestre-Ferrandiz, Jorge
    Franklin, Matthew
    de Pouvourville, Gerard
    VALUE IN HEALTH, 2023, 26 (04) : 20 - 31
  • [46] Augmenting the randomized controlled trial with real-world data to aid clinical decision making in metastatic renal cell carcinoma: a systematic review and meta-analysis
    Moran, Michael
    Nickens, Dana
    Adcock, Katherine
    Bennetts, Meg
    Charnley, Natalie
    Fife, Kate
    FUTURE ONCOLOGY, 2019, 15 (34) : 3987 - 4001
  • [47] UK Stakeholder Perspectives on Surrogate Endpoints in Cancer, and the Potential for UK Real-World Datasets to Validate Their Use in Decision-Making
    Baldwin, David
    Carmichael, Jonathan
    Cook, Gordon
    Navani, Neal
    Peach, James
    Slater, Ruth
    Wheatstone, Pete
    Wilkins, Julia
    Allen-Delingpole, Nicola
    Kerr, Cicely E. P.
    Siddiqui, Khalid
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 791 - 810
  • [48] Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model
    Li, Meng
    Chen, Shengqi
    Lai, Yunfeng
    Liang, Zuanji
    Wang, Jiaqi
    Shi, Junnan
    Lin, Haojie
    Yao, Dongning
    Hu, Hao
    Ung, Carolina Oi Lam
    FRONTIERS IN MEDICINE, 2021, 8
  • [49] Use of Real-World Data Sources for Canadian Drug Pricing and Reimbursement Decisions: Stakeholder Views and Lessons for Other Countries
    Husereau, Don
    Nason, Edward
    Ahuja, Tarun
    Nikai, Enkeleida
    Tsakonas, Eva
    Jacobs, Philip
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2019, 35 (03) : 181 - 188
  • [50] COVID-19 Distribution in Pregnancy, Drug Use Patterns and COVID-19 Medication during the Pandemic in Spain: Data from Real-World Electronic Health Records
    Mota-Perez, Mercedes
    Huerta-alvarez, Consuelo
    Llorente, Ana
    Cea-Soriano, Lucia
    PHARMACEUTICALS, 2024, 17 (02)